EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Salivary Calprotectin Is not a Useful Biomarker to Monitor Disease Activity in Patients with Inflammatory Bowel Disease

Vincent Bos, Femke Crouwel, Petra Waaijenberg, Gerd Bouma, Marjolijn Duijvestein, Hans Jc Buiter, Henk S Brand, Henrike M Hamer, Nanne K De Boer

Journal of Gastrointestinal and Liver Diseases · 15.09.2022 · 31 (3) · 283-289

DOI: 10.15403/jgld-4215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 15.09.2022. Verfasst von Vincent Bos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Deptartment of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. vincen…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Non-invasive biomarkers are gaining interest for monitoring disease activity in patients with inflammatory bowel diseases (IBD). Fecal calprotectin is a reliable biomarker but patients often report the collection of feces being unpleasant and cumbersome. In this study, we aimed to assess if salivary calprotectin could be used as a non-invasive biomarker to determine disease activity instead of fecal calprotectin.

Methods

In this cross-sectional explorative cohort study, stimulated saliva was collected from patients with an established IBD diagnosis and healthy controls. The concentration of calprotectin in saliva was determined by a particle-enhanced turbidimetric immunoassay. Intestinal disease activity was assessed with fecal calprotectin levels and the Harvey-Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI). Missing data were handled using multiple imputation.

Results

Sixty-three patients (41 Crohn’s disease and 22 ulcerative colitis) and 11 controls were included. Patients had a mean fecal calprotectin of 138.78 µg/g and a median salivary calprotectin of 1.87 mg/L. No significant correlation was found between salivary calprotectin and fecal calprotectin levels (p=0.495). When patients were stratified in two subgroups based on a fecal calprotectin cut-off value of 250 µg/g, there were no significant differences in salivary calprotectin levels between both patient groups (p=0.641) and between patients and healthy controls (p=0.248). Also, salivary, and fecal calprotectin levels were not significantly different when stratifying patients in two subgroups, active disease and remission, using HBI/SCCAI scores.

Conclusions

Salivary calprotectin does not correlate to fecal calprotectin and disease activity scores in patients, making it unreliable for assessing IBD activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeInflammatory Bowel DiseasesBiomarkersCohort StudiesCross-Sectional StudiesFecesHumansLeukocyte L1 Antigen ComplexSeverity of Illness Index

Substanzen

BiomarkersLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Deptartment of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. vincent.bos@icloud.com.
  • Dept. of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Deptartment of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Deptartment of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Deptartment of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam; Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, T…
  • Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Zitieren

APA

Bos, V., Crouwel, F., Waaijenberg, P., Bouma, G., Duijvestein, M., Buiter, H. J., Brand, H. S., Hamer, H. M., & De Boer, N. K. (2022). Salivary Calprotectin Is not a Useful Biomarker to Monitor Disease Activity in Patients with Inflammatory Bowel Disease. Journal of Gastrointestinal and Liver Diseases, 31(3), 283-289. https://doi.org/10.15403/jgld-4215

Vancouver

Bos V, Crouwel F, Waaijenberg P, Bouma G, Duijvestein M, Buiter HJ, et al. Salivary Calprotectin Is not a Useful Biomarker to Monitor Disease Activity in Patients with Inflammatory Bowel Disease. Journal of Gastrointestinal and Liver Diseases. 2022;31(3):283-289. doi:10.15403/jgld-4215

BibTeX
@article{Bos2022,
  author = {Bos, Vincent and Crouwel, Femke and Waaijenberg, Petra and Bouma, Gerd and Duijvestein, Marjolijn and Buiter, Hans Jc and Brand, Henk S and Hamer, Henrike M and De Boer, Nanne K},
  title = {Salivary Calprotectin Is not a Useful Biomarker to Monitor Disease Activity in Patients with Inflammatory Bowel Disease},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2022},
  volume = {31},
  number = {3},
  pages = {283--289},
  doi = {10.15403/jgld-4215}
}
Kostenlos starten →